BOULE DIAGNOSTICS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.25 SEK | 0.00% |
|
+1.49% | -8.65% |
| May. 08 | Boule Diagnostics AB Appoints Rikke Rytter as Director | CI |
| May. 07 | Transcript : Boule Diagnostics AB, Q1 2024 Earnings Call, May 07, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,324 | 1,155 | 947.5 | 586.4 | 435.7 | 398 | - | - |
| Enterprise Value (EV) 1 | 1,395 | 1,206 | 1,014 | 594.6 | 495.9 | 445.3 | 438.6 | 429.8 |
| P/E ratio | 35.3 x | -24.1 x | 41.7 x | 33.6 x | 17.5 x | 10.7 x | 9.14 x | 8.09 x |
| Yield | 0.88% | 0.92% | 1.13% | - | - | 2.29% | 3.37% | 3.9% |
| Capitalization / Revenue | 2.65 x | 2.88 x | 2.05 x | 1.07 x | 0.76 x | 0.69 x | 0.65 x | 0.6 x |
| EV / Revenue | 2.8 x | 3.01 x | 2.19 x | 1.08 x | 0.87 x | 0.77 x | 0.72 x | 0.65 x |
| EV / EBITDA | 14.9 x | 21.7 x | 14.9 x | 10.6 x | 7.76 x | 5.26 x | 4.75 x | 4.21 x |
| EV / FCF | -68.1 x | 41.3 x | -76.8 x | -6.88 x | -15.8 x | -234 x | 14.8 x | 13.2 x |
| FCF Yield | -1.47% | 2.42% | -1.3% | -14.5% | -6.31% | -0.43% | 6.75% | 7.57% |
| Price to Book | 3.98 x | 4.29 x | 3.2 x | 1.27 x | 0.92 x | 0.77 x | 0.72 x | 0.68 x |
| Nbr of stocks (in thousands) | 19,417 | 19,417 | 19,417 | 38,833 | 38,833 | 38,833 | - | - |
| Reference price 2 | 68.20 | 59.50 | 48.80 | 15.10 | 11.22 | 10.25 | 10.25 | 10.25 |
| Announcement Date | 2/7/20 | 2/3/21 | 2/3/22 | 2/2/23 | 2/6/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 498.9 | 400.5 | 463.3 | 548.1 | 571.3 | 579 | 609 | 658.6 |
| EBITDA 1 | 93.9 | 55.7 | 68.1 | 56.1 | 63.9 | 84.66 | 92.31 | 102.2 |
| EBIT 1 | 70 | -5.9 | 36 | 29 | 39.3 | 55.93 | 62.84 | 71.15 |
| Operating Margin | 14.03% | -1.47% | 7.77% | 5.29% | 6.88% | 9.66% | 10.32% | 10.8% |
| Earnings before Tax (EBT) 1 | 50.6 | -49 | 28.8 | 20.8 | 30.1 | 47.97 | 54.82 | 61.97 |
| Net income 1 | 37.5 | -48 | 23.3 | 12.7 | 25 | 37.33 | 43.53 | 49.21 |
| Net margin | 7.52% | -11.99% | 5.03% | 2.32% | 4.38% | 6.45% | 7.15% | 7.47% |
| EPS 2 | 1.930 | -2.470 | 1.170 | 0.4500 | 0.6400 | 0.9613 | 1.121 | 1.267 |
| Free Cash Flow 1 | -20.5 | 29.2 | -13.2 | -86.4 | -31.3 | -1.9 | 29.6 | 32.55 |
| FCF margin | -4.11% | 7.29% | -2.85% | -15.76% | -5.48% | -0.33% | 4.86% | 4.94% |
| FCF Conversion (EBITDA) | - | 52.42% | - | - | - | - | 32.06% | 31.85% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 68% | 66.15% |
| Dividend per Share 2 | 0.6000 | 0.5500 | 0.5500 | - | - | 0.2350 | 0.3450 | 0.4000 |
| Announcement Date | 2/7/20 | 2/3/21 | 2/3/22 | 2/2/23 | 2/6/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 140.3 | 132.5 | 140.8 | 125.6 | 149.2 | 143.1 | 140.5 | 139.6 | 148.1 | 147.8 | 143.8 | 135.1 | 148.8 |
| EBITDA 1 | 24.1 | 16.3 | 12.2 | 11.8 | 15.8 | 18.4 | 21.6 | 14.2 | 15.9 | 26.2 | 20.78 | 19.07 | 22.3 |
| EBIT 1 | 13.8 | 10.3 | 5 | 3.6 | 10 | 12.1 | 8.7 | 7.9 | 10.5 | 19.1 | 13.68 | 11.97 | 15.2 |
| Operating Margin | 9.84% | 7.77% | 3.55% | 2.87% | 6.7% | 8.46% | 6.19% | 5.66% | 7.09% | 12.92% | 9.52% | 8.86% | 10.22% |
| Earnings before Tax (EBT) 1 | 11.5 | 6.9 | 4.2 | 1.8 | 8 | 10.6 | 5.2 | 5.3 | 8.9 | 13.3 | 11.68 | 9.885 | 13.11 |
| Net income 1 | 17.3 | 4.6 | 2.9 | 2.4 | 2.9 | 7.9 | 4.1 | 4.6 | 8.4 | 9.8 | 9.271 | 7.849 | 10.41 |
| Net margin | 12.33% | 3.47% | 2.06% | 1.91% | 1.94% | 5.52% | 2.92% | 3.3% | 5.67% | 6.63% | 6.45% | 5.81% | 7% |
| EPS 2 | 0.8700 | 0.2300 | 0.1400 | 0.1200 | 0.0900 | 0.2000 | 0.1100 | 0.1200 | 0.2200 | 0.2500 | 0.2388 | 0.2021 | 0.2681 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/3/22 | 5/4/22 | 7/18/22 | 11/10/22 | 2/2/23 | 5/3/23 | 7/24/23 | 11/9/23 | 2/6/24 | 5/7/24 | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 71.2 | 50.8 | 66.6 | 8.2 | 60.2 | 47.3 | 40.5 | 31.7 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 0.7583 x | 0.912 x | 0.978 x | 0.1462 x | 0.9421 x | 0.5587 x | 0.439 x | 0.3105 x |
| Free Cash Flow 1 | -20.5 | 29.2 | -13.2 | -86.4 | -31.3 | -1.9 | 29.6 | 32.6 |
| ROE (net income / shareholders' equity) | 11.9% | -15.9% | 8.25% | 3.35% | 5.33% | 7.08% | 8.13% | 8.8% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 17.20 | 13.90 | 15.20 | 11.90 | 12.20 | 13.40 | 14.20 | 15.10 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 6.1 | 4.6 | 3.1 | 6.4 | 6.9 | 6 | 7 | 7 |
| Capex / Sales | 1.22% | 1.15% | 0.67% | 1.17% | 1.21% | 1.04% | 1.15% | 1.06% |
| Announcement Date | 2/7/20 | 2/3/21 | 2/3/22 | 2/2/23 | 2/6/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
10.25
SEK
Average target price
10.9
SEK
Spread / Average Target
+6.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.65% | 37.67M | |
| +0.20% | 203B | |
| +3.65% | 178B | |
| +31.11% | 157B | |
| +32.35% | 112B | |
| +2.74% | 64.58B | |
| +22.60% | 56.33B | |
| -3.27% | 46.75B | |
| -9.79% | 36.59B | |
| -0.58% | 35.09B |
- Stock Market
- Equities
- BOUL Stock
- Financials Boule Diagnostics AB
